Drugs / F-18 RGD-K5
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT00743353 | Aug 2008 → Jan 2009 | breast cancer, lung cancer, malignant glioma, melanoma +1 | Siemens Molecular Imaging | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00988936 | Sep 2009 → Mar 2012 | breast cancer, colorectal cancer, non-small cell lung carcinoma | Siemens Molecular Imaging | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | F-18 RGD-K5 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00743353 ↗ |
| Known as | (18)F-RGD-K5 | “2-((2S,5R,8S,11S)-5-benzyl-8-(4-((2S,3R,4R,5R,6S)-6-((2-(4-(3-(18)F-fluoropropyl)-1H-1,2,3-triazol-1-yl)acetamido)methyl)-3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxamido)butyl...” PMID 22499613 ↗ Apr 2012 |
| Modality | Diagnostic / imaging agent | “F-18 RGD-K5 is being investigated as a diagnostic radiopharmaceutical” NCT00743353 ↗ |
| Route | Intravenous | “after intravenous injection of (18)F-RGD-K5” PMID 22499613 ↗ Apr 2012 |